Skip to content

Immune Checkpoint Inhibitor- versus Chemotherapy-associated Rheumatoid Arthritis: A Single-Center, Retrospective Cohort Study

Immune Checkpoint Inhibitor- versus Chemotherapy-associated Rheumatoid Arthritis: A Single-Center, Retrospective Cohort Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600118029
Enrollment
Unknown
Registered
2026-01-31
Start date
2026-02-01
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

Immune checkpoint inhibitors group:Noners)

Sponsors

The First Affiliated Hospital of Guilin Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years, confirmed malignancy; 2. Diagnosis of rheumatoid arthritis in accordance with the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria for RA, with the diagnosis confirmed by two rheumatology specialists; 3. have been treated with immune checkpoint inhibitors (PD-1/PD-L1/CTLA-4 inhibitors) or conventional chemotherapeutic agents; 4. have a complete clinical history of at least 12 months and at least 5 follow-up visits in the rheumatology and oncology departments of our centre from the time of RA diagnosis. 5. The diagnosis of rheumatoid arthritis in all patients should meet the 2010 American College of Rheumatology (ACR, American College of Rheumatology)/European League Against Rheumatism (EULAR, The European League Against Rheumatism) classification criteria for RA.

Exclusion criteria

Exclusion criteria: 1. diagnosis of rheumatoid arthritis before the diagnosis of malignancy; 2. severe hepatic and renal insufficiency (Child-Pugh class C or eGFR < 30 ml/min/1.73m²); 3. concurrent treatment with conventional chemotherapeutic agents and immune checkpoint inhibitors prior to the onset of arthritis symptoms; 4. treatment with a biologic agent targeting B-cells, such as rituximab, prior to the onset of arthritis symptoms; 5. loss of follow-up or incomplete key clinical information during follow-up; patients with less than 5 follow-up visits within 1 year from baseline.

Design outcomes

Primary

MeasureTime frame
DAS28-CRP;

Secondary

MeasureTime frame
VAS(Visual Analogue Scale for Pain Assessment);C-reactive protein;Average dose of glucocorticoids;

Countries

China

Contacts

Public ContactXu Jia

The First Affiliated Hospital of Guilin Medical University

1993830041@qq.com+86 134 5765 7640

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026